Afluria

ApprovedBiologic

NNational Heart, Lung, and Blood Institute (NHLBI)

Afluria is one of 48 biologic programs targeting Lymphoma. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaRecruiting

InfluenzaActive, not recruiting

LymphomaApproved

Recruiting

InfluenzaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Afluria

NNational Heart, Lung, and Blood Institute (NHLBI)

Approved

1 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 5

Tafasitamab

Incyte

Preclinical

7 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Nuvigil

NNuvo Research GmbH

Preclinical

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

ApprovedRecruiting

Lymphoma

NCT05170399

Clinical

Trials by Indication[1]

Influenza1 trial

Immune Responses Induced by Different Licensed Influenza Vaccines

Completed·UUniversity of Massachusetts, Worcester·N/A·NCT00902278·193 enrolled

Adult1 trial

Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age

Completed·PProtein Sciences Corporation·Phase 3·NCT01825200·2,640 enrolled

Lymphoma1 trial

Vaccine Responses in Patients With B Cell Malignancies

Recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Approved·NCT05170399·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Afluria. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Afluria compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Afluria. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Heart, Lung, and Blood Institute (NHLBI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: NNational Heart, Lung, and Blood Institute (NHLBI)

Afluria

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Influenza1 trial

Adult1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News